Trastuzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC) targeted at HER2, has recently gained approval in the USA and Europe for treating HER2-low breast cancer, which is currently defined as IHC scores of 1+ or 2+ without ERBB2 ISH amplification. Here, ERBB2 is linked to breast carcinoma.